A Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of 601 Versus Ranibizumab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Latest Information Update: 18 Jan 2023
At a glance
- Drugs 601 A (Primary) ; Ranibizumab
- Indications Branch retinal vein occlusion; Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms BRVO
- Sponsors Sunshine Guojian Pharmaceutical
Most Recent Events
- 11 Jan 2023 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.
- 11 Jan 2023 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.
- 11 Jan 2023 Status changed from not yet recruiting to recruiting.